Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

Psychopharmacology

Volumn 232, Issue 5, 2015, Pages 907-915

  Falcon, Edgardo ^a   Maier, Kaitlyn ^a   Robinson, Shivon A ^a   Hill Smith, Tiffany E ^a   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressant; Anxiety; Buprenorphine; Depression; Dopamine; Kappa opioid receptor; Microdialysis

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BUPRENORPHINE; DESIPRAMINE; DOPAMINE; KAPPA OPIATE RECEPTOR; MORPHINE SULFATE; NORBINALTORPHIMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NALTREXONE; NARCOTIC AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL TEST; FORCED SWIM TEST; IMMOBILITY; LATENT PERIOD; LOCOMOTION; MALE; MOUSE; NONHUMAN; NOVELTY INDUCED HYPOPHAGIA TEST; NUCLEUS ACCUMBENS; TRANQUILIZING ACTIVITY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DEPRESSION; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BUPRENORPHINE; DEPRESSION; DESIPRAMINE; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NALTREXONE; NARCOTICS; NUCLEUS ACCUMBENS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SWIMMING;

EID: 84922826918     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3723-y     Document Type: Article

References (56)

1. Al-Harbi KS (2012) Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Pref Adherence 6:369-388
2. Andrews CM, Lucki I (2001) Effects of cocaine on extracellular dopamine and serotonin levels in the nucleus accumbens. Psychopharmacology 155:221-229
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95
4. Balu DT, Hodes GE, Anderson BT, Lucki I (2009) Enhanced sensitivity of the MRL/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharm 34:1764-1773
5. Bechtolt AJ, Valentino RJ, Lucki I (2008) Overlapping and distinct brain regions associated with the anxiolytic effects of chlordiazepoxide and chronic fluoxetine. Neuropsychopharmacology 33:2117-2130
6. Bodkin JA, Zornberg GL, Lukas SE, Cole JO (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15(1):49-57
7. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141
8. Brown SM, Holtzman M, Kim T, Kharasch ED (2011) Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 115:1251-1260
9. Carr GV, Lucki I (2010) Comparison of the kappa opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology 210:295-302
10. Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I (2010) Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 35:752-763
11. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758
12. Cowan A (2007) Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68-72
13. Cowan A, Lewis JW (eds) (1995) Buprenorphine: combating drug abuse with a unique opioid. Wiley-Liss, New York
14. Crowley JJ, Jones MD, O'Leary OF, Lucki I (2004) Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 78:269-274
15. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM (2002) The impact of treatment-resistant depression on health care utilization and costs. Clin Psychiatry 63(11):963-971
16. Cryan JF, Sweeney FF (2011) The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol 164:1129-1161
17. Cryan JF, Page ME, Lucki I (2005) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 182:335-344
18. Dalvi A, Lucki I (1999) Murine models of depression. Psychopharmacology 147:14-16
19. Davis MP (2012) Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 10(6):209-219
20. Detke MJ, Johnson J, Lucki I (1997) Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5:107-112
21. DiChiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067-1080
22. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-783
23. Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321-1330
24. Ehrich E, Turncliff R, Sellers E, Jones R, Fava M (2012) Early clinical development of the opioid modulator ALKS 5461 in the treatment of depression. NCDEU
25. Fostick L, Silberman A, Beckman M, Spivak B, Amital D (2010) The economic impact of depression: resistance or severity? Eur Neuropsychopharm 20:671-675
26. Franklin KBJ, Paxinos G (2004) The mouse brain in stereotaxic coordinates. Academic, San Diego
27. Glover EM, Davis M (2008) Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology 198:167-180
28. Gringauz M, Rabinowitz R, Stav A, Korczyn AD (2001) Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. J Anesth 15:204-209
29. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695
30. Ipser JC, Terburg D, Syal S, Phillips N, Solms M, Paksepp J, Malcolm-Smith S, Thomas K, Stein DJ, van Honk J (2013) Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 38:166-170
31. Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC (2011) Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 213:509-520
32. Karp JF, Butters MA, Begley A, Miller MD, Lenze EJ, Blumberger D, Mulsant B, Reynolds III CF (2014) Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in mid-life and older adults. J Clin Psychiatry in press
33. Kessler RC, Chiu WT, Demier O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):617-627
34. 1B autoreceptors in different brain regions of the mouse. J Pharmacol Exp Ther 298:1083-1091
35. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA (2007) Anxiolytic-like effects of kappa opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323:838-845
36. Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 70:425-433
37. Kosten TR, Morgan C, Kosten TA (1990) Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat 7:51-54
38. Leander DJ (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445-1447
39. Lelong-Boulouard V, Quentin T, Moreaux F, Debruyne D, Boulouard M, Coquerel A (2006) Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse. Drug Alcohol Depen 85:103-113
40. Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155:315-322
41. Lufty K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402
42. Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36(3):195-206
43. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330
44. Maisonneuve IM, Archer S, Glick SD (1994) U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60
45. Marquez P, Ballram R, Kieffer BL, Lufty K (2007) The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52:1336-1341
46. McLaughlin JP, Marton-Popovici M, Chavkin C (2003) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683
47. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (2006) Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31:1241-1248
48. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256
49. Nyhuis PW, Gastpar M, Scherbaum N (2008) Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 28(5):593-595
50. Paronis CA, Bergman J (2011) Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther 336:488-495
51. Richards ML, Sadee W (1985) Buprenorphine is an antagonist at the kappa opioid receptor. Pharmacol Res 2:178-181
52. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS (2004) Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90:1258-1268
53. Shmygalev S, Damm M, Weckbecker K, Berghaus G, Petzke F, Sabatowski R (2011) The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug Alcohol Depend 117:190-197
54. Tenore PL (2008) Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 27:49-65
55. Van't Veer A, Carlezon WA (2013) Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 229:435-452
56. Zomkowski ADE, Santos ARS, Rodrigues ALS (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381:279-283